Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus maintenance after platinum-etoposide for metastatic neuroendocrine carcinoma
2014-003951-72Phase 2Active
- Sponsor
- Gruppo Oncologico Italiano di Ricerca Clinica
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of everolimus in neuroendocrine carcinoma (NEC) (2 arms), sponsored by Gruppo Oncologico Italiano di Ricerca Clinica. Primary endpoint: Progression-free survival. Started Jan 2015; status: active.
02
Drugs
everolimus
03
Conditions
neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on 2014-003951-72.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-003951-72.